DUBLIN, Jan. 22, 2019 /PRNewswire/ -
The "PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets" report has been added to ResearchAndMarkets.com's offering.
Phosphoinositide 3-kinases (PI3K) are a family of lipid kinases that transduce signals from a range of growth factors and cytokines into intracellular messages by generating phospholipids. This in turn activates the serine/threonine kinase AKT (AKT), as well as other downstream effectors such as mammalian target of rapamycin (mTOR) and forkhead box O (FOXO).
The PI3K pathway is a critical signal transduction pathway and plays important roles in the regulation of many cellular processes including protein synthesis, cell-cycle progression and cell survival. Additionally, numerous diseases are known to be associated with dysregulated PI3K signaling.
This is particularly the case for cancers, with the pathway being recognized as perhaps the most commonly activated signaling pathway in human cancer. However, PI3K signaling has also been associated with several other disease areas including disorders of the gastrointestinal, metabolic and central nervous systems.
The following report discusses the significance of the PI3K pathway, including its role in disease, and provides a comprehensive overview of the PI3K marketed and pipeline landscapes. The report provides a breakdown of the following key signaling pathways within the PI3K network in terms of marketed and pipeline activity: PI3K/AKT/mTOR pathway, Ras/Raf/MEK/ERK pathway, cell survival pathways downstream of AKT, cell-cycle progression pathways downstream of AKT, metabolism pathways downstream of AKT and kinases downstream of phosphoinositide-dependent kinase-1 (PDK1).
An analysis of the marketed and pipeline activity across various nodes (defined as groups of molecules which have the same role in response to a stimulus) within each of these pathways is provided. An examination of the marketed and pipeline products acting on each of these pathways in terms of molecule type and therapy area, and, in the case of pipeline products, novelty and stage of development, provides further granularity.
Additionally, detailed product profiles of key marketed products are provided, which incorporate clinical and commercial perspectives and include historical and forecast annual sales revenues. The report concludes with a discussion of promising late-stage pipeline products.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Role of PI3K in Disease
2.1.2 Central Nervous System
2.1.3 Ulcerative Colitis
3 Marketed Products Landscape
3.2 Key Signaling Pathways within the PI3K Marketed Product Landscape
3.2.1 PI3K/AKT/mTOR Pathway
3.2.2 Ras/Raf/MEK/ERK Pathway
3.2.3 Cell Survival Pathways Downstream of AKT
3.2.4 Cell Cycle Progression Pathways Downstream of AKT
3.2.5 Kinases Downstream of PDK1
3.3 Key Marketed Products
4 Pipeline Products Landscape
4.2 Key Signaling Pathways within the PI3K Pipeline Product Landscape
4.2.1 PI3K/AKT/mTOR Pathway
4.2.2 Ras/Raf/MEK/ERK Pathway
4.2.3 Cell Survival Pathways Downstream of AKT
4.2.4 Cell Cycle Progression Pathways Downstream of AKT
4.2.5 Metabolism Pathways Downstream of AKT
4.2.6 Kinases Downstream of PDK1
4.2.7 Clinical-Stage Pipeline Products
4.2.8 List of All Pipeline Products
For more information about this report visit https://www.researchandmarkets.com/research/czfskv/global_pi3k?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets